# Low dose of ints-tcv PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/low-dose-of-ints-tcv

> The next catalyst for low dose of ints-tcv, sponsored by GSK plc (GSK), is its topline data readout, Apr to Jul 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | low dose of ints-tcv |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Salmonella Infections](https://sec-api.dev/indications/salmonella-infections) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Salmonella Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286370 (A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286370

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Salmonella Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286370 (A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286370

## Same indication

- [Ints-gmma dose c](https://sec-api.dev/pdufa/ints-gmma) (GSK)

Calendar months: [April 2028](https://sec-api.dev/fda-calendar/2028-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/low-dose-of-ints-tcv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Low dose of ints-tcv PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/low-dose-of-ints-tcv

```bibtex
@misc{secapidev_pdufa_low_dose_of_ints_tcv_20261116,
  title        = {Low dose of ints-tcv PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/low-dose-of-ints-tcv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_low_dose_of_ints_tcv_20261116","title":"Low dose of ints-tcv PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/low-dose-of-ints-tcv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
